{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:22:08Z","timestamp":1783430528895,"version":"3.54.6"},"reference-count":51,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Nonadherence to direct oral anticoagulant (DOAC) pharmacotherapy may increase the risk of thromboembolism or bleeding, and delayed or missed doses are the most common types of nonadherence. Current recommendations from regulatory agencies or guidelines regarding this issue lack evidence and fail to consider individual differences. This study aimed to develop individual remedial dosing strategies when the dose was delayed or missed for DOACs, including rivaroxaban, apixaban, edoxaban, and dabigatran etexilate. Remedial dosing regimens based on population pharmacokinetic (PK)-pharmacodynamic (PD) modeling and simulation strategies were developed to expeditiously restore drug concentration or PD biomarkers within the therapeutic range. Population PK-PD characteristics of DOACs were retrieved from previously published literature. The effects of factors that influence PK and PD parameters were assessed for their impact on remedial dosing regimens. A web-based dashboard was established with R-shiny to recommend remedial dosing regimens based on patient traits, dosing schedules, and delay duration. Addressing delayed or missed doses relies on the delay time and specific DOACs involved. Additionally, age, body weight, renal function, and polypharmacy may marginally affect remedial strategies. The proposed remedial dosing strategies surpass current recommendations, with less deviation time beyond the therapeutic range. The online dashboard offers quick and convenient solutions for addressing missed or delayed DOACs, enabling individualized remedial dosing strategies based on patient characteristics to mitigate\u00a0the risks of bleeding and thrombosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013854","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T21:19:39Z","timestamp":1726694379000},"page":"5906-5916","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-3274","authenticated-orcid":false,"given":"Xiao-Qin","family":"Liu","sequence":"first","affiliation":[{"name":"1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6740-6003","authenticated-orcid":false,"given":"Zi-Ran","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-361X","authenticated-orcid":false,"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"13","key":"2024112214504890300_bib1","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2024112214504890300_bib2","doi-asserted-by":"crossref","first-page":"684638","DOI":"10.3389\/fphar.2021.684638","article-title":"Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice","volume":"12","author":"Roberti","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"2024112214504890300_bib3","doi-asserted-by":"crossref","first-page":"e005969","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2024112214504890300_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12872-019-1033-3","article-title":"Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?","volume":"19","author":"Pham","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"2024112214504890300_bib5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2018.1428543","article-title":"Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants","volume":"34","author":"Deshpande","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2024112214504890300_bib6","doi-asserted-by":"crossref","first-page":"e0301421","DOI":"10.1371\/journal.pone.0301421","article-title":"Relationship between electronically monitored adherence to direct oral anticoagulants and ischemic or hemorrhagic events after an initial ischemic stroke-A case control study","volume":"19","author":"Rekk","year":"2024","journal-title":"PLoS One"},{"issue":"23","key":"2024112214504890300_bib7","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"2024112214504890300_bib8","unstructured":"US Food and Drug Administration\n          . FDA online label repository. 2024. Accessed 1 April 2024. https:\/\/labels.fda.gov\/."},{"key":"2024112214504890300_bib9","unstructured":"Electronic medicines compendium. 2024. Accessed 1 April 2024. https:\/\/www.medicines.org.uk\/emc\/."},{"key":"2024112214504890300_bib10","unstructured":"Medsafe; New Zealand Medicines and Medical Devices Safety Authority. Data Sheets and Consumer Medicine Information (CMI)\n          . . 2024. Accessed 1 April 2024. medsafe.govt.nz\/Medicines\/infoSearch.asp."},{"key":"2024112214504890300_bib11","unstructured":"European Medicine Agency. 2024. Accessed 1 April 2024. https:\/\/www.ema.europa.eu\/en\/search."},{"issue":"10","key":"2024112214504890300_bib12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"5","key":"2024112214504890300_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/psp4.12288","article-title":"Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations","volume":"7","author":"Willmann","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"2024112214504890300_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcph.288","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF","volume":"54","author":"Girgis","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"2024112214504890300_bib15","first-page":"453","article-title":"Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"issue":"5","key":"2024112214504890300_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"issue":"9","key":"2024112214504890300_bib17","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1038\/psp.2014.34","article-title":"Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery","volume":"3","author":"Leil","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"2024112214504890300_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/psp4.12830","article-title":"Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease","volume":"11","author":"Willmann","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"2024112214504890300_bib19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/jth.15277","article-title":"Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism","volume":"19","author":"R\u00f6shammar","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024112214504890300_bib20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/bloodadvances.2017013805","article-title":"Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients","volume":"2","author":"Yoshioka","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2024112214504890300_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17512433.2021.1937126","article-title":"How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing","volume":"14","author":"Liu","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"2024112214504890300_bib22","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/bcp.15316","article-title":"How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy","volume":"89","author":"Yin","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2024112214504890300_bib23","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1111\/jth.15104","article-title":"The relationship between DOAC levels and clinical outcomes: the measures tell the tale","volume":"18","author":"Toorop","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024112214504890300_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/asheducation.V2015.1.117.3916182","article-title":"Monitoring and reversal of direct oral anticoagulants","volume":"2015","author":"Cuker","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2024112214504890300_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"issue":"1","key":"2024112214504890300_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.blre.2016.08.006","article-title":"Measurement and reversal of the direct oral anticoagulants","volume":"31","author":"Samuelson","year":"2017","journal-title":"Blood Rev"},{"issue":"9","key":"2024112214504890300_bib27","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000201604","article-title":"Handling delayed or missed dose of antiseizure medications: a model-informed individual remedial dosing","volume":"100","author":"Li","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"2024112214504890300_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13318-019-00598-0","article-title":"How to handle delayed or missed doses: a population pharmacokinetic perspective","volume":"45","author":"Gu","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024112214504890300_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.phrs.2015.08.020","article-title":"How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation","volume":"100","author":"Saint-Marcoux","year":"2015","journal-title":"Pharmacol Res"},{"key":"2024112214504890300_bib30","article-title":"Model-based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese patients with tuberculosis","author":"Li","year":"3  2024","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2024112214504890300_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/pharmaceutics12040297","article-title":"Changing the drug delivery system: does it add to non-compliance ramifications control? A simulation study on the pharmacokinetics and pharmacodynamics of atypical antipsychotic drug","volume":"12","author":"Elkomy","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"2024112214504890300_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.nmd.2021.02.014","article-title":"Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen","volume":"31","author":"MacCannell","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"2024112214504890300_bib33","unstructured":"Nick\n              H\n            \n          . Simulations with\/without residual error. 2009. Accessed 26 August 2024. https:\/\/www.mail-archive.com\/nmusers@globomaxnm.com\/msg01817.html."},{"issue":"4","key":"2024112214504890300_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2133\/dmpk.DMPK-12-RG-109","article-title":"Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients","volume":"28","author":"Kaneko","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"2024112214504890300_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics15020588","article-title":"Is a lower dose of rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of rivaroxaban","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"2024112214504890300_bib36","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/bcp.13561","article-title":"Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation","volume":"84","author":"Ueshima","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2024112214504890300_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/psp4.12184","article-title":"Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism","volume":"6","author":"Byon","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"2024112214504890300_bib38","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2024112214504890300_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/psp4.12347","article-title":"Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation","volume":"7","author":"Cirincione","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"2024112214504890300_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1160\/TH11-09-0656","article-title":"A\u00a0combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery","volume":"107","author":"Dansirikul","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"2024112214504890300_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11538-021-00976-3","article-title":"Designing drug regimens that mitigate nonadherence","volume":"84","author":"Counterman","year":"2021","journal-title":"Bull Math Biol"},{"issue":"6","key":"2024112214504890300_bib42","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10928-021-09777-6","article-title":"What should patients do if they miss a dose of medication? A theoretical approach","volume":"48","author":"Counterman","year":"2021","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"4","key":"2024112214504890300_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-022-09812-0","article-title":"Should patients skip late doses of medication? A pharmacokinetic perspective","volume":"49","author":"Clark","year":"2022","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"3","key":"2024112214504890300_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10928-023-09897-1","article-title":"How drug onset rate and duration of action affect drug forgiveness","volume":"51","author":"Clark","year":"2024","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"2","key":"2024112214504890300_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ehjqcco\/qcab054","article-title":"Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) registry","volume":"9","author":"Guo","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"2024112214504890300_bib46","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/10600280231155489","article-title":"Trajectories of oral anticoagulation adherence and associated clinical outcomes during long-term anticoagulation among Medicare beneficiaries with venous thromboembolism","volume":"57","author":"Park","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2024112214504890300_bib47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2024112214504890300_bib48","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/bcp.12727","article-title":"Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and\/or pulmonary embolism - the Hokusai-VTE phase 3 study","volume":"80","author":"Niebecker","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2024112214504890300_bib49","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"2","key":"2024112214504890300_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"2024112214504890300_bib55","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"Novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5906\/2314888\/blooda_adv-2024-013854-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5906\/2314888\/blooda_adv-2024-013854-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T14:51:06Z","timestamp":1732287066000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5906\/517889\/Handling-delayed-or-missed-direct-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":51,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013854","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}